GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanxi C&Y Pharmaceutical Group Co Ltd (SZSE:300254) » Definitions » EV-to-Revenue

Shanxi C&Y Pharmaceutical Group Co (SZSE:300254) EV-to-Revenue : 3.31 (As of May. 26, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Shanxi C&Y Pharmaceutical Group Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Shanxi C&Y Pharmaceutical Group Co's enterprise value is ¥2,669.7 Mil. Shanxi C&Y Pharmaceutical Group Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥805.6 Mil. Therefore, Shanxi C&Y Pharmaceutical Group Co's EV-to-Revenue for today is 3.31.

The historical rank and industry rank for Shanxi C&Y Pharmaceutical Group Co's EV-to-Revenue or its related term are showing as below:

SZSE:300254' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.41   Med: 2.65   Max: 12.6
Current: 3.31

During the past 13 years, the highest EV-to-Revenue of Shanxi C&Y Pharmaceutical Group Co was 12.60. The lowest was 1.41. And the median was 2.65.

SZSE:300254's EV-to-Revenue is ranked worse than
61.33% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 2.285 vs SZSE:300254: 3.31

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-26), Shanxi C&Y Pharmaceutical Group Co's stock price is ¥11.86. Shanxi C&Y Pharmaceutical Group Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥3.34. Therefore, Shanxi C&Y Pharmaceutical Group Co's PS Ratio for today is 3.55.


Shanxi C&Y Pharmaceutical Group Co EV-to-Revenue Historical Data

The historical data trend for Shanxi C&Y Pharmaceutical Group Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanxi C&Y Pharmaceutical Group Co EV-to-Revenue Chart

Shanxi C&Y Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.78 2.25 2.43 2.57 3.46

Shanxi C&Y Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.47 2.38 3.28 3.46 3.29

Competitive Comparison of Shanxi C&Y Pharmaceutical Group Co's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Shanxi C&Y Pharmaceutical Group Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanxi C&Y Pharmaceutical Group Co's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanxi C&Y Pharmaceutical Group Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Shanxi C&Y Pharmaceutical Group Co's EV-to-Revenue falls into.



Shanxi C&Y Pharmaceutical Group Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Shanxi C&Y Pharmaceutical Group Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=2669.713/805.613
=3.31

Shanxi C&Y Pharmaceutical Group Co's current Enterprise Value is ¥2,669.7 Mil.
Shanxi C&Y Pharmaceutical Group Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥805.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanxi C&Y Pharmaceutical Group Co  (SZSE:300254) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Shanxi C&Y Pharmaceutical Group Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=11.86/3.338
=3.55

Shanxi C&Y Pharmaceutical Group Co's share price for today is ¥11.86.
Shanxi C&Y Pharmaceutical Group Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3.34.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanxi C&Y Pharmaceutical Group Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shanxi C&Y Pharmaceutical Group Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanxi C&Y Pharmaceutical Group Co (SZSE:300254) Business Description

Traded in Other Exchanges
N/A
Address
No.53, Hubin Street, Economic and Technological Development Zone, Datong, CHN, 037010
Shanxi C&Y Pharmaceutical Group Co Ltd is engaged in the production, research and development, and sales of pharmaceutical products. The company offers pregnancy products and services, anti-infective, and urinary health.
Executives
Zuo Xue Min Supervisors
Huang Le Qun Director
Zhang Zhen Biao Executives
Yu Jun Xian Directors, Directors, and Executives
Zhao Qun Director
Weng Zhan Guo Director
Geng Chun Feng Director
Pang Xiao Quan Supervisors
Zhong Hai Rong Directors, executives
Xuan Hang Director

Shanxi C&Y Pharmaceutical Group Co (SZSE:300254) Headlines

No Headlines